{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T06:01:30Z","timestamp":1785045690682,"version":"3.55.0"},"posted":{"date-parts":[[2026,6,29]]},"group-title":"In Review","reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,17]]},"abstract":"<title>Abstract<\/title>\n                <p>Lupus myositis (LM) is an underrecognized entity, whose pathological features significantly overlap with idiopathic inflammatory myopathies (IIMs). Currently, no standardized histopathological criteria or immunohistochemical (IHC) markers exist for the diagnosis of LM on muscle biopsy. We performed detailed histologic, immunohistochemical, ultrastructural, and spatial transcriptomic protein analyses on a stringent cohort of LM muscle biopsies, excluding patients with myositis-specific autoantibodies (MSA). Findings were compared with dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (ASyS), and non-diseased control muscle specimens. Among 1736 patients diagnosed with systemic lupus erythematosus (SLE) between 2010 and 2023, 32 muscle biopsies were identified in myositis patients without MSA. Twenty-two cases demonstrated a necrotizing myopathy with spatial and temporal heterogeneity, MxA-positive myofiber expression, and perivascular inflammation composed of mixed T and B cells. A \u201cpan-fascicular necrotizing myopathy\u201d pattern was a highly recognizable feature of LM, although minority of cases demonstrated a diffuse scattered or perifascicular damage pattern. An IHC profile of MxA+\/MHC I+\/MHC II+ reliably distinguished LM from other IIMs. Spatial transcriptomics analysis confirmed that type I interferon pathway or MHC I related mRNAs and proteins were the most deferentially expressed in myofibers, capillaries and inflammatory cells. Electron microscopy identified frequent endothelial tubuloreticular inclusions. The remaining 10 cases demonstrated nonspecific myositis on muscle biopsy and were clinically associated with significant higher frequencies of overlapping systemic rheumatologic features such as interstitial lung disease, Sicca syndrome, systemic sclerosis, and rheumatoid arthritis, suggesting overlap myositis rather than pure LM. In conclusion, the pathological hallmark of LM is a type I interferon driven necrotizing myopathy with perivascular mixed T and B cell inflammation. A combined IHC panel including MxA, MHC I and MHC II effectively differentiates LM from other inflammatory myopathies.<\/p>","DOI":"10.21203\/rs.3.rs-10072964\/v1","type":"posted-content","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:47:38Z","timestamp":1782748058000},"source":"Crossref","is-referenced-by-count":0,"title":["Lupus myositis, a type I interferon driven necrotizing myopathy with regional heterogeneity"],"prefix":"10.21203","author":[{"given":"Arpita","family":"Beechar","sequence":"first","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Bermas","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengsong","family":"Zhu","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Xing","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Trivedi","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Bhai","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan S.","family":"Reisch","sequence":"additional","affiliation":[{"name":"Biostatistics\uff0c University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Rajaram","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Daoud","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Cai","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000635","article-title":"Clinical and histopathological features of myositis in systemic lupus erythematosus","volume":"9","author":"Tiniakou E","year":"2022","unstructured":"Tiniakou E, Goldman D, Corse A, Mammen A, Petri MA (2022) Clinical and histopathological features of myositis in systemic lupus erythematosus. Lupus Sci Med ;9","journal-title":"Lupus Sci Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0961203320918021","article-title":"Inflammatory myositis in systemic lupus erythematosus","volume":"29","author":"Bitencourt N","year":"2020","unstructured":"Bitencourt N, Solow EB, Wright T, Bermas BL (2020) Inflammatory myositis in systemic lupus erythematosus. Lupus 29:776\u2013781","journal-title":"Lupus"},{"key":"ref3","author":"Allenbach Y","year":"2016","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W (2016) 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October Neuromuscular disorders: NMD 2018;28:87\u201399"},{"key":"ref4","author":"Mammen AL","year":"2019","unstructured":"Mammen AL, Allenbach Y, Stenzel W, Benveniste O (2019) 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018. Neuromuscular disorders: NMD"},{"key":"ref5","author":"Stenzel W","year":"2023","unstructured":"Stenzel W, Mammen AL, Gallay L et al (2023) 273rd ENMC International workshop: Clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27\u201329 October Neuromuscular disorders: NMD 2024;45:104453"},{"key":"ref6","author":"Lilleker JB","year":"2024","unstructured":"Lilleker JB, Naddaf E, Saris CGJ, Schmidt J, de Visser M, Weihl CC (2024) 272nd ENMC international workshop: 10 Years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318 June 2023, Hoofddorp, The Netherlands. Neuromuscular disorders: NMD ;37:36\u201351"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","article-title":"An update on autoantibodies in the idiopathic inflammatory myopathies","volume":"21","author":"Allameen NA","year":"2025","unstructured":"Allameen NA, Ramos-Lisbona AI, Wedderburn LR, Lundberg IE, Isenberg DA (2025) An update on autoantibodies in the idiopathic inflammatory myopathies. Nat Rev Rheumatol 21:46\u201362","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","author":"Bleecker JL","year":"2015","unstructured":"De Bleecker JL, De Paepe B, Aronica E et al (2015) 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28\u201330 March 2014, Naarden, The Netherlands. Neuromuscular disorders: NMD. ;25:268\u2013272"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Damoiseaux J, Mammen AL, Piette Y, Benveniste O, Allenbach Y (eds) 256(th) ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8\u201310 October 2021. Neuromuscular disorders: NMD 2022","DOI":"10.1016\/j.nmd.2022.05.011"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies","volume":"75","author":"Mariampillai K","year":"2018","unstructured":"Mariampillai K, Granger B, Amelin D et al (2018) Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol 75:1528\u20131537","journal-title":"JAMA Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis A","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-0035-1558980","article-title":"Clinical Evaluation and Management of Inflammatory Myopathies","volume":"35","author":"Chhibber S","year":"2015","unstructured":"Chhibber S, Amato AA (2015) Clinical Evaluation and Management of Inflammatory Myopathies. Semin Neurol 35:347\u2013359","journal-title":"Semin Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00401-023-02669-8","article-title":"Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases","volume":"147","author":"Nelke C","year":"2024","unstructured":"Nelke C, Schmid S, Kleefeld F et al (2024) Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases. Acta Neuropathol 147:15","journal-title":"Acta Neuropathol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond","volume":"41","author":"Caielli S","year":"2023","unstructured":"Caielli S, Wan Z, Pascual V (2023) Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. Annu Rev Immunol 41:533\u2013560","journal-title":"Annu Rev Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mus.28066","article-title":"Myxovirus resistance protein A (MxA) expression in myositides: Sarcoplasmic expression is common in both dermatomyositis and lupus myositis","volume":"69","author":"Xing C","year":"2024","unstructured":"Xing C, Trivedi J, Bitencourt N, Burns DK, Reisch JS, Cai C (2024) Myxovirus resistance protein A (MxA) expression in myositides: Sarcoplasmic expression is common in both dermatomyositis and lupus myositis. Muscle Nerve 69:548\u2013555","journal-title":"Muscle Nerve"},{"key":"ref16","first-page":"1400","volume-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","author":"Aringer M","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus, vol 71. Arthritis & rheumatology, Hoboken, NJ, pp 1400\u20131412"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40478-020-01007-3","article-title":"Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups","volume":"8","author":"Nguyen M","year":"2020","unstructured":"Nguyen M, Do V, Yell PC et al (2020) Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups. Acta Neuropathol Commun 8:125","journal-title":"Acta Neuropathol Commun"},{"key":"ref18","volume-title":"Dermatomyositis: Muscle Pathology According to Antibody Subtypes","author":"Tanboon J","year":"2021","unstructured":"Tanboon J, Inoue M, Saito Y et al (2021) Dermatomyositis: Muscle Pathology According to Antibody Subtypes. Neurology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel W","year":"2015","unstructured":"Stenzel W, Preu\u00dfe C, Allenbach Y et al (2015) Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 84:1346\u20131354","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jns.2008.11.010","article-title":"Inflammatory myopathies with mitochondrial pathology and protein aggregates","volume":"278","author":"Temiz P","year":"2009","unstructured":"Temiz P, Weihl CC, Pestronk A (2009) Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 278:25\u201329","journal-title":"J Neurol Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1096\/fj.04-3660fje","article-title":"Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells","volume":"19","author":"Manoli I","year":"2005","unstructured":"Manoli I, Le H, Alesci S et al (2005) Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells. Faseb j 19:1359\u20131361","journal-title":"Faseb j"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10072964\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10072964\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:55:43Z","timestamp":1785045343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10072964\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":21,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10072964\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,29]]},"subtype":"preprint"}}